Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic Cardiomyopathy

There is an unmet medical need to treat patients with severe hypertrophic cardiomyopathy leading to heart failure and death in children carrying pathogenic activating variants in the RAS/mitogen-activated protein kinase pathway. A retrospective analysis of 61 patients provides evidence for decreased mortality and morbidity with improved cardiac status in patients with RASopathy with severe hypertrophic cardiomyopathy receiving mitogen-activated protein kinase kinase inhibition (n = 30) vs those with standard-of-care treatment (n = 31). Side effects were not life threatening and were manageable. The data presented suggest that personalized therapies targeting underlying signaling pathway abnormalities might be effective in critically ill patients with RASopathy warranting clinical investigation.

Authors

Institutions

Publication Details

Journal
JACC Basic to Translational Science
Published
2024-12-04
DOI
https://doi.org/10.1016/j.jacbts.2024.10.002
Citations
17
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
6.83
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic Cardiomyopathy

Jake Kleinmahon, Giovanni Battista Ferrero, Marie‐Ange Delrue, Gabrielle Norrish et al.
17 citations
JACC Basic to Translational Science
Cardiomyopathy and Myosin Studies
6.83
article

Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic Cardiomyopathy

Jake Kleinmahon, Giovanni Battista Ferrero, Marie‐Ange Delrue, Gabrielle Norrish, Jos Draaisma, Martin Zenker, Andreas Hahn, Christopher Marquis, Cordula M. Wolf, Laurence Vaujois, Joshua K. Meisner, Mariska Kemna, David M. Peng, Tiina Ojala, Floris E.A. Udink ten Cate, Paul F. Kantor, Juan Pablo Kaski, Mette Møller Handrup, Peter Ewert, Michael Hofbeck, Olga Boleti, Tim Friede, Stefan Rupp, Adrian Dancea, Derek G. Human, Birgit Donner, Irena Odri Komazec, Niti Dham, Danielle Gottlieb Sen, Anja Hanser, Soujanya Bogarapu, Marie‐Josée Raboisson, Yves Théorêt, Bruce D. Gelb, Mark W. W. Russell, Grégor Andelfinger, Terence Prendiville, Christopher Hart, Martin Krueger, Daniela Reber, Alessandro Mussa, Frank Dicke
article en
17 citations

Abstract

There is an unmet medical need to treat patients with severe hypertrophic cardiomyopathy leading to heart failure and death in children carrying pathogenic activating variants in the RAS/mitogen-activated protein kinase pathway. A retrospective analysis of 61 patients provides evidence for decreased mortality and morbidity with improved cardiac status in patients with RASopathy with severe hypertrophic cardiomyopathy receiving mitogen-activated protein kinase kinase inhibition (n = 30) vs those with standard-of-care treatment (n = 31). Side effects were not life threatening and were manageable. The data presented suggest that personalized therapies targeting underlying signaling pathway abnormalities might be effective in critically ill patients with RASopathy warranting clinical investigation.

JACC Basic to Translational ScienceVol. 10(2)
George Washington University Hospital (US), Seattle Children's Hospital (US), Children's National (US), Children's Hospital of Los Angeles (US), Innsbruck Medical University (AT), Johns Hopkins University (US), Radboud University Nijmegen (NL), Illinois College (US), University of Calgary (CA), Justus-Liebig-Universität Gießen (DE), Universitätsklinikum Gießen und Marburg (DE), University of Michigan (US), University Hospital Bonn (DE), Johns Hopkins Medicine (US), Montreal Children's Hospital (CA), Great Ormond Street Hospital (GB), Alberta Children's Hospital (CA), Centre Hospitalier Universitaire Sainte-Justine (CA), Radboud University Medical Center (NL), Children's Health Ireland at Crumlin (IE), University of Illinois Chicago (US), München Klinik Schwabing (DE), Radboud Institute for Molecular Life Sciences (NL), Child Health and Development Institute (US), Amalia Kinderziekenhuis (NL), University Children's Hospital Tübingen (DE), University Children’s Hospital Basel (CH), German Centre for Cardiovascular Research (DE), Comer Children's Hospital (US), University Hospital Magdeburg (DE), ERN GUARD-Heart (NL), Pediatrics and Genetics (US), Giessen School of Theology (DE), Deutsches Herzzentrum München (DE), BC Children's Hospital (CA), Jefferson Hospital for Neuroscience (US), Université Laval (CA), University College London (GB), University of Turin (IT), University of Tübingen (DE), Otto-von-Guericke-Universität Magdeburg (DE), Icahn School of Medicine at Mount Sinai (US)
Openalex Percentile: Top 2%
Cardiomyopathy and Myosin Studies
6.83
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.